- Home
- SPT vs LRMR Comparison
SPT vs LRMR Comparison
Compare SPT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPT | LRMR |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.7M | 455.8M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SPT | LRMR |
|---|---|---|
| Price | $10.47 | $3.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $11.75 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 1.3M | 857.9K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $457,547,000.00 | N/A |
| Revenue This Year | $8.86 | N/A |
| Revenue Next Year | $8.04 | $1,816.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.72 | N/A |
| 52 Week Low | $4.92 | $2.72 |
| 52 Week High | $14.90 | $6.42 |
Technical Indicators
Market Signals| Indicator | SPT | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.